Longevity Health Holdings, Inc. (XAGE) reported revenue of $1.91M and net income of -$6.91M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Longevity Health Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $1.91M | $50.32K | $0 |
| Cost of revenue | $818.05K | $6.36K | $0 |
| Gross profit | $1.09M | $43.96K | $0 |
| Operating income | -$7.11M | -$5.00M | -$5.94M |
| Net income | -$6.91M | -$10.37M | -$15.45M |
| Research & development | $788.89K | $1.05M | $2.50M |
| Weighted-average diluted shares | shares 1.43M | Unavailable | shares 11.02M |
| Pretax income | -$6.87M | -$10.75M | -$16.21M |
| Income tax expense | $36.26K | -$97.28K | $0 |
| Diluted EPS | $-4.83 | $-14.56 | $-1.46 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable |
| General & administrative | Unavailable | Unavailable | Unavailable |
| Selling & marketing | $1.42M | $189.32K | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash & equivalents | $706.74K | $157.14K | $2.91M |
| Total assets | $2.37M | $1.47M | $63.95M |
| Current assets | $1.95M | $955.55K | $62.90M |
| Total liabilities | $8.23M | $6.19M | $39.20M |
| Current liabilities | $7.92M | $5.88M | $38.50M |
| Total equity incl. NCI | -$5.87M | -$4.71M | $24.75M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable |
| Inventory | $963.03K | $108.70K | $0 |
| Accounts receivable | $36.50K | $4.10K | $0 |
| Goodwill | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable |
| Accounts payable | $4.49M | $4.06M | $4.42M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating cash flow | -$3.33M | -$3.89M | -$8.35M |
| Capital expenditures | $14.22K | Unavailable | $30.47K |
| Investing cash flow | -$164.22K | -$748.80K | -$30.47K |
| Financing cash flow | $4.04M | $1.89M | $11.16M |
| Net change in cash | Unavailable | Unavailable | Unavailable |
| Stock-based compensation | $692.79K | $827.04K | $667.68K |
| Common dividends paid | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | $0 |
| Depreciation & amortization | $78.68K | $83.49K | $97.11K |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free cash flow | -$3.34M | Unavailable | -$8.38M |
| Gross margin | 57.2% | 87.4% | Unavailable |
| Operating margin | -371.6% | -9933.8% | Unavailable |
| FCF margin | -174.8% | Unavailable | Unavailable |
| SBC / revenue | 36.2% | 1643.6% | Unavailable |
| Current ratio | 0.25x | 0.16x | 1.63x |
| Revenue YoY growth | 3701.4% | Unavailable | Unavailable |
| Net margin | -361.0% | -20605.5% | Unavailable |
| R&D / revenue | 41.2% | 2095.3% | Unavailable |
| CapEx / revenue | 0.7% | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open XAGE in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.